AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and ...

Korean firms pursue botulinum toxin market amid rising global demand Pharmaceutical companies capitalize on expanding ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...

Casting is open. Allergan Aesthetics is on the search for women to inspire women as one of the Faces of Natrelle. The ...

AbbVie was once a division of the leading medical device company, Abbott Laboratories. The drugmaker started trading on the market in 2013, and since then, it has delivered market-beating returns.

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from both football games and daytime programming.

AbbVie cautions that these forward-looking statements ... which will continue to differentiate the brand versus oral competitors. Rinvoq is now capturing more than 20% in-place share in atopic ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...